Search

Your search keyword '"Crestani, Bruno"' showing total 995 results

Search Constraints

Start Over You searched for: Author "Crestani, Bruno" Remove constraint Author: "Crestani, Bruno" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
995 results on '"Crestani, Bruno"'

Search Results

2. Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants.

4. New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome

5. Clinical characteristics and outcomes of respiratory syncytial virus-associated ARF in immunocompetent patients: A seven-year experience at a tertiary hospital in France

11. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia

12. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

13. Detection and Early Referral of Patients With Interstitial Lung Abnormalities An Expert Survey Initiative

16. MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression

17. Human inherited CCR2 deficiency underlies progressive polycystic lung disease

20. 2022 Update of indications and contraindications for lung transplantation in France

21. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update. Full-length version

22. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis

23. Correction to: New Dominant‑Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130‑Dependent Hyper‑IgE Syndrome

24. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis

25. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

28. Updates on the controversial roles of regulatory lymphoid cells in idiopathic pulmonary fibrosis.

29. Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative

30. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

31. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

32. Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort

34. COVID-19 PBMCs are doubly harmful, through LDN-mediated lung epithelial damage and monocytic impaired responsiveness to live Pseudomonas aeruginosa exposure

35. Impact of Air Pollution and MUC5B Genotype on Survival in Idiopathic Pulmonary Fibrosis

36. Low income and outcome in idiopathic pulmonary fibrosis: An association to uncover

37. The Genetics of Interstitial Lung Diseases

38. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

39. Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis

40. RPA3-UMAD1 rs12702634 and rheumatoid arthritis–associated interstitial lung disease in European ancestry

41. RPA3-UMAD1 rs12702634 and rheumatoid arthritis-associated interstitial lung disease in European ancestry

44. Chronic interstitial lung disease associated with systemic lupus erythematosus: A multicentric study of 89 cases.

45. Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors.

46. Rheumatoid arthritis and idiopathic pulmonary fibrosis: a bidirectional Mendelian randomisation study.

49. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis

50. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Catalog

Books, media, physical & digital resources